CDC7 Inhibitors
AssigneeEli Lilly and Company
InventorsRobert Dean DALLY, Timothy Andrew WOODS
Life of this patent
Estimating the term…
Abstract
The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer.
Claims41
-16. (canceled)
A compound which is 3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)isoindolin-1-one, or a pharmaceutically acceptable salt or hydrate thereof.
A pharmaceutical composition comprising a compound which is 3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)isoindolin-1-one, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
A method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound which is 3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)isoindolin-1-one, or a pharmaceutically acceptable salt or hydrate thereof.
Dependencies are inferred from the claim text.